Study guide
3.7 Screening Testing (including Newborn Screening)
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
3.7 Screening Testing (including Newborn Screening)
Key Takeaways Explain This Topic AI
Screening tests risk-stratify asymptomatic populations; they are not definitive diagnoses and require confirmatory testing after positive screens.
Wilson–Jungner principles (condition importance, acceptable test, treatment availability, program infrastructure) conceptually justify public screening programs such as newborn screening (NBS).
NBS prioritizes treatable conditions of early onset; positive screens generate urgency for confirmatory labs and specialty referral, not immediate lifelong labeling from the screen alone.
False positives, incidental findings (for example, carrier status or maternal disease on some platforms), and residual risk after negative screens are core counseling themes.
Population screening differs from diagnostic testing in pretest probability, consent model, and how results change next steps.
Last updated: August 2026
Screening vs diagnostic testing
Feature Screening Diagnostic testing
Population Asymptomatic or average-risk groups (or defined high-risk screen cohorts) Individuals with phenotype or high clinical suspicion
- Pretest probability Usually low Higher
- Goal Risk stratification; identify who needs more testing Establish or refute a specific diagnosis
Positive result meaning Increased risk / needs confirmation Supports a clinical-molecular diagnosis (with correlation)
Negative result meaning Lowered but not always zero residual risk Does not always exclude disease (assay limits)
Program design Sensitivity prioritized; some false positives accepted Specificity and interpretive accuracy emphasized
One-line board definition: Screening sorts; diagnosis decides. A newborn screen “positive for possible PKU” is not the same as a biochemical + molecular confirmation of phenylketonuria.
Wilson–Jungner principles (conceptual, high-yield)
The classic Wilson–Jungner criteria (WHO, 1968) were written for public health screening generally. Genetic counselors are not expected to recite every historical bullet verbatim, but you must recognize the spirit of justified screening:
- Principle (conceptual) Application to genetic NBS
- Important health problem Early-onset conditions with serious morbidity/mortality
Accepted treatment / management Dietary therapy, enzyme replacement, antibiotics, transplant pathways, etc.
- Facilities for diagnosis and treatment Confirmatory labs, metabolic/genetics clinics, care networks
- Recognizable latent or early stage Presymptomatic newborns
- Suitable test Acceptable dried-blood-spot assays with defined cutoffs
- Test acceptable to population Heel-stick programs embedded in perinatal care
- Natural history understood Enough to know early treatment helps
- Agreed policy on whom to treat Protocols for screen-positive infants
- Cost balanced vs case-finding Public health program economics
- Continuous process, not one-off Quality assurance, follow-up, panel review
Modern genomic NBS debates ask whether actionability , parental interest , and equity should expand panels beyond classic Wilson–Jungner thresholds. For the exam, flag when a stem proposes screening for an untreatable adult-onset condition in newborns without program infrastructure—that usually fails screening logic.
- Newborn screening (NBS): what counselors must know
- Core features
Timing: Dried blood spot typically collected ~24–48 hours after birth (state protocols vary).
Mandate model: Most U.S. NBS is public health–mandated with limited parental opt-out (varies by jurisdiction)—distinct from clinical diagnostic consent.
Recommended Uniform Screening Panel (RUSP): Federal advisory list that states largely follow but may expand; exact conditions remain state-specific .
Condition classes: Inborn errors of metabolism, endocrinopathies, hemoglobinopathies, cystic fibrosis, hearing loss screening (physiologic), critical congenital heart disease (pulse oximetry), spinal muscular atrophy and SCID in many programs, and others as panels evolve.
From screen to diagnosis — the pathway
Primary screen (often tandem mass spectrometry for metabolites; DNA assays for some conditions; enzyme/immunoreactive trypsinogen algorithms for CF).
Out-of-range / positive / borderline result triggers urgent contact.
Confirmatory testing (plasma amino acids, urine organic acids, enzyme assay, diagnostic gene testing, sweat chloride, immunology studies, etc.).
Specialty management begins based on confirmatory results—not on the screen alone.
Screen result language Counselor translation
Negative / in-range Condition much less likely; residual risk remains (timing, transfusion, mild variants, lab error)
- Borderline / inconclusive Repeat screen or additional labs; avoid premature reassurance or alarm
- Positive / out-of-range Needs prompt confirmatory evaluation; not a final diagnosis
Carrier detection (some DNA-based screens) May identify infant carriers or parental implications without disease
False positives and why they happen
NBS cutoffs favor sensitivity (miss fewer true cases), so false positives are expected. Contributors include:
- Prematurity, total parenteral nutrition, illness, or timing of collection
- Carrier status or mild biochemical variants that cross cutoffs
Maternal conditions affecting the neonate’s metabolites (for example, maternal vitamin B12 deficiency patterns)
Laboratory or sample quality issues
Counseling stance after a positive screen: Acknowledge parental anxiety, explain that most screen-positives are not confirmed disease for many conditions, but emphasize why rapid follow-up still matters —true positives need early treatment.
False negatives and residual risk
A negative NBS does not eliminate clinical vigilance. Late-onset variants, conditions not on the state panel, sample collected too early, transfusion effects, and rare assay failures can produce missed cases. If the phenotype later suggests a screenable disease, pursue diagnostic testing regardless of NBS history.
Other genetic screening contexts (beyond NBS)
Domain 3B “screening” also includes:
- Context Example Key counseling point
- Prenatal aneuploidy screening NIPT, serum analytes Screen ≠ diagnostic CVS/amnio
Carrier screening Expanded panels (see next section) Reproductive risk, not personal disease diagnosis for AR carriers
Population cancer screening genes (emerging/ limited) Not equivalent to indication-based hereditary cancer testing Criteria and utility differ from diagnostic oncology genetics
Cascade “screening” language misuse Relatives tested for known variant That is cascade/predictive testing, not population screening
Trap: Calling NIPT a “diagnostic test for Down syndrome” is wrong; diagnostic confirmation requires diagnostic prenatal procedures/cytogenomic testing.
Consent, equity, and psychosocial issues in screening programs
Mandated NBS still deserves understandable education; parents may not recall what was screened.
Incidental findings on DNA-based NBS (carrier status, variants related to adult disease, maternal disease signals) create counseling complexity.
Equity: Program quality depends on follow-up access; a “free screen” without reachable confirmatory care fails Wilson–Jungner infrastructure expectations.
Stigma and labeling: Avoid treating screen-positive infants as diagnosed until confirmatory testing completes.
Worked scenario A
Parents call frantically: “The state says our baby is positive for maple syrup urine disease.” Best response elements: validate fear; explain screening vs diagnosis; arrange same-day/urgent metabolic confirmatory labs and clinical evaluation; advise holding dietary changes only as directed by the metabolic team; do not wait weeks for a routine pediatric visit.
Worked scenario B
A toddler presents with developmental regression; NBS was normal. Can the child still have a metabolic disorder? Yes —residual risk and non-panel conditions remain. Proceed with phenotype-driven diagnostic evaluation.
Worked scenario C
A health system proposes screening all newborns with genome sequencing for adult-onset Alzheimer risk alleles. Critique using screening principles: limited early treatment benefit, psychosocial harm, right-not-to-know for the child, and weak fit with classic public-health screening justification.
Exam scenarios and traps
Trap — treating a positive screen as a diagnosis. Confirmation is mandatory.
Trap — absolute reassurance after negative NBS when clinical suspicion is high.
Trap — applying diagnostic pretest counseling scripts unchanged to mandated NBS. Consent models differ, but education and follow-up counseling still matter.
Trap — confusing carrier screening with NBS. Different goals, timing, and result meanings.
Scenario: CF NBS algorithms may use IRT ± DNA; an identified infant carrier needs parental counseling and possibly parental testing, not a CF diagnosis for the infant.
Practice checkpoints
Contrast screening vs diagnostic goals in one table in your mind.
Name why false positives are tolerated in NBS.
List what happens after an out-of-range newborn screen.
Apply Wilson–Jungner thinking to reject poorly justified genomic screens.